Get the Stockscreener App
5.91
3.90%
-0.24
After Hours:
5.90
-0.010
-0.17%
Immunitybio Inc stock is traded at $5.91, with a volume of 24.08M.
It is down -3.90% in the last 24 hours and up +189.71% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$6.15
Open:
$6.15
24h Volume:
24.08M
Relative Volume:
1.03
Market Cap:
$5.82B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-6.0928
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-19.48%
1M Performance:
+189.71%
6M Performance:
+132.68%
1Y Performance:
+87.03%
1-Day Range:
$5.7314
$6.35
1-Week Range:
$5.54
$7.8755
52-Week Range:
$1.83
$8.28
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
5.91 | 6.06B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.44 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.72 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.79 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say - statnews.com
A High-Stakes Surge for ImmunityBio Shares - AD HOC NEWS
Positive Regulatory Developments and Stellar Growth for ImmunityBio - AD HOC NEWS
ImmunityBio Surges on Trial Success and Saudi FDA Approvals - timothysykes.com
ImmunityBio Stocks Surge Amid Clinical Advances and Strategic Growth - StocksToTrade
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run - Finviz
ImmunityBio Shares Pull Back Following Significant Advance - AD HOC NEWS
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Morningstar
How Is The Market Feeling About ImmunityBio Inc? - Benzinga
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research - MSN
Is It Too Late To Reassess ImmunityBio (IBRX) After The Recent Oncology Headlines? - Yahoo Finance UK
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - AOL.com
ImmunityBio, Inc. (IBRX) Stock Analysis: Potential Upside Of 90% For This Biotech Innovator - DirectorsTalk Interviews
ImmunityBio Stock Surge Backed by Strong Fundamentals - AD HOC NEWS
Undercovered Dozen: Incyte, Annaly Capital, ImmunityBio And More - Seeking Alpha
ImmunityBio Glioblastoma Data Add Fuel To Rapidly Moving IBRX Story - simplywall.st
Clinical Data Fuels Investor Enthusiasm for ImmunityBio - AD HOC NEWS
FDA Requests More Data, IBRX Shares Fall - timothysykes.com
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
FDA Inquiry Pushes ImmunityBio Shares Down in Pre-Market - StocksToTrade
ImmunityBio rally causes $492M paper losses for short sellers - MSN
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next - TechStock²
IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research - Stocktwits
HC Wainwright Issues Positive Forecast for ImmunityBio (NASDAQ:IBRX) Stock Price - MarketBeat
Short Sellers Face Mounting Pressure as ImmunityBio Shares Rebound - AD HOC NEWS
H.C. Wainwright raises Immunitybio stock price target to $10 on ANKTIVA progress - Investing.com UK
H.C. Wainwright raises Immunitybio stock price target to $10 on ANKTIVA progress By Investing.com - Investing.com South Africa
ImmunityBio amends $505 million convertible note to allow partial conversions - Investing.com
Aug PostEarnings: Is ImmunityBio Inc stock a smart retirement pickJuly 2025 Intraday Action & Safe Entry Trade Reports - baoquankhu1.vn
ImmunityBio Amends Major Insider Convertible Note Agreement - TipRanks
ImmunityBio Signs Convertible Note Amendment With Nant Capital - TradingView
Why ImmunityBio Shares Are Sinking Despite Analyst Buzz - TipRanks
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy - BioSpace
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday - TechStock²
ImmunityBio Stock Surges on Strong Commercial Momentum and Regulatory Wins - AD HOC NEWS
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year - AOL.com
Why ImmunityBio (IBRX) Is Up 16.8% After New ANKTIVA Data, FDA Progress And Saudi Approvals - simplywall.st
USA–Saudi Biotech Alliance Summit Marks a New Era in Healthspan, Immunotherapy, and Global Scientific Partnership - ImmunityBio
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week - TechStock²
IBRX stock sees volatile session – ImmunityBio’s update in phase 2 glioblastoma trial sparks buzz - MSN
ImmunityBio Shares Tumble Following Mixed Trial Data - AD HOC NEWS
Why ImmunityBio Stock Is Skyrocketing Again Today - AOL.com
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is It Too Late To Consider ImmunityBio (IBRX) After Its Recent Share Price Surge? - Sahm
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month - Yahoo Finance
ImmunityBio, Inc. (IBRX) stock: slides as shares drop 4.91% despite promising GBM trial results - parameter.io
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study - Clinical Trials Arena
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz - Stocktwits
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update - TechStock²
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):